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Introduction
Colorectal cancer (CRC) is the fourth most frequent cause of cancer-
specific death in Korea [1]. Peritoneal carcinomatosis (PC) of colorectal
origin is common and is the second-most frequent cause of death in CRC
after metastatic disease to the liver. PC may cause serious complications,
including intestinal obstruction, massive ascites, and hydronephrosis,
which are associated clinically with abdominal pain and fullness, vomit-
ing, constipation, malnutrition, and renal dysfunction. The incidence of
PC during potentially curative surgery for primary CRC was reported as
3% to 28%, which may be explained by differences in methods to detect
cancer cells [2]. Mechanisms of PC development are still controversial,
and include spreading of free cancer cells due to serosal involvement of
the primary tumor, lymphatic and or venous dissemination of malignant
cells, and implantation of free cancer cells due to the presence of adherence
molecules [3]. It would appear that the mechanisms responsible are mul-
tifactorial. Three principal studies [4-6] showed the natural history of PC
from CRC, and confirmed a poor prognosis with a median survival rang-
ing between 6 and 8 months and no 5-year survivors. Because of its poor
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Purpose
Peritoneal carcinomatosis (PC) of colorectal cancer (CRC) is common and is the second most
common cause of death. Clinical studies regarding chemotherapy for CRC with PC have been
classically rather limited in scope. We evaluated the efficacy of modified oxaliplatin, leucovorin,
and fluorouracil (m-FOLFOX4) regimen for PC of CRC origin.
Materials and Methods
CRC patients with PC were treated with cycles of oxaliplatin at 85 mg/m2on day 1, leucovorin 20
mg/m2followed by 5-fluorouracil (5-FU) via a 400 mg/m2bolus and a 22 hours continuous infusion
of 600 mg/m25-FU on days 1-2 at 2-week intervals.
Results
Forty patients participated in this study. Median age was 55 years. Thirty-two patients (80.0%) re-
ceived previous operation, and 60.0% of PC occurred synchronously. Thirty-five patients (87.5%)
were assessable and exhibited measurable lesions. Two patients (5.7%) demonstrated complete
response and five patients (14.3%) showed partial response. The median time to progression was
4.4 months (95% confidence interval, 2.5 to 6.3 months), the median overall survival time was 21.5
months (95% confidence interval, 17.2 to 25.7 months). There was no treatment related death.
Presence of liver metastasis (p=0.022), performance status (p=0.039), and carcinoembryonic anti-
gen level (p=0.016) were related to the time to progression. Patients with low carcinoembryonic
antigen level (37.2  months vs. 15.6 months, p=0.001) or good performance status (22.5 months vs.
6.8 months, p=0.040) showed better overall survival.
Conclusion
The m-FOLFOX4 regimen was determined to be effective for CRC patients with PC. 
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prognosis, PC from CRC has previously been considered a preterminal
condition suitable only for palliative treatment.
Sugarbaker et al. introduced cytoreductive surgery (CRS) and hyper-
thermic intraperitoneal chemotherapy (HIPEC) as anew innovative ther-
apeutic option for selected patients with PC to improve long-term survival
for selected patients [7]. Recently, it was reported that a 5-year survival
rate of 51% and median survival of 63 months in patients with limited
PC treated with oxaliplatin-based HIPEC [8]. While the initial results uti-
lizing these techniques have been promising, caution must be exercised
before recommending them as first-line treatment modalities. In the liter-
ature, morbidity and mortality rates after CRS and HIPEC range from
25% to 41% and from 0% to 8%, respectively [9]. Furthermore, the ma-
jority of patients with PC from CRC present with an unresectable disease
at the time of diagnosis, therefore CRS and HIPEC is not indicated for
those patients.
In the past two decades, chemotherapeutic treatment of patients with
metastatic CRC has rapidly evolved. The FOLFOX regimen of oxaliplatin
and infused fluorouracil (5-FU) plus leucovorin (LV) is active and com-
paratively safe. It is considered as a standard therapy for patients with ad-
vanced CRC [10]. We previously reported a median time to progression
(TTP) of 8.7 months, response rate of 45%, and median survival time of
19.5 months for metastatic CRC using modified FOLFOX4 (m-FOL-
FOX4) regimen [11]. Nonetheless, the patient cohorts with Stage IV dis-
ease in these trials failed to include patients with PC. The difficulties of
including these patients are a result of the inability to image sub-centimeter
peritoneal lesions and assess tumor response on the Response Evaluation
Criteria in Solid Tumors (RECIST) criteria. Thus, only a few reports are
currently available regarding the efficacy of systemic chemotherapy
against PC.
The studies investigating the prognosis of isolated PC treated with
chemotherapy showed median survival lasting from 5.2 to 12.6 months
[4-6, 12]. However, in these studies, only 5-FU-based chemotherapy was
administered without modern drugs like oxaliplatin or irinotecan.
The aim of this study was to evaluate the safety and efficacy of oxali-
platin with low dose LV and bolus and continuous infusion 5-FU (m-
FOLFOX4) for the treatment of patients with CRC with PC. 
Materials  and  Methods
1. Patients
Patients were required to have a histologically-confirmed adenocarci-
noma arising in the colon or rectum. All patients had PC with or without
measurable lesions, a performance status≤2 according to the Eastern Co-
operative Oncology Group (ECOG) scale, adequate bone marrow and
renal function, and age between 18 and 75 years. Exclusion criteria in-
cluded the presence of central nervous system metastases, serious or un-
controlled concurrent medical illness, and a history of other malignancies.
Patients with synchronous disease were diagnosed at the time of presen-
tation with CRC, either on routine staging, computed tomography (CT),
or at laparotomy. Patients with metachronous carcinomatosis were
deemed to be clear of peritoneal disease at the initial curative colorectal
resection, but subsequently became symptomatic on follow-up and were
diagnosed with peritoneal metastases on CT. The study was approved by
the local ethics committee, and informed consent was obtained from all
patients before study entry.
2. Treatment protocols and dose modification
On day 1, oxaliplatin (85 mg/m2) was administered by intravenous (IV)
infusion in 500 mL of normal saline or dextrose over 2 hours IV infusion.
On days 1 and 2, LV (20 mg/m2) was administered as an IV bolus, im-
mediately followed by 5-FU (400 mg/m2) given as a 10 minute IV bolus,
followed by 5-FU (600 mg/m2) as a continuous 22 hours infusion, with a
light shield. Dose modifications of oxaliplatin or 5-FU were made for
hematologic, gastrointestinal, or neurologic toxicities on the basis of the
most severe grade of toxicity that had occurred during the previous cycle.
Treatment could be delayed for up to 2 weeks if symptomatic toxicity
persisted, or if the absolute number of neutrophils was lower than
1,500/ʼL; platelets count was lower than 100,000/ʼL. The 5-FU dose was
reduced by 25% for subsequent courses after occurrence of National Can-
cer Institute Common Toxicity Criteria (NCI-CTC) grade 3 diarrhea,
stomatitis, or dermatitis. The dose of oxaliplatin was reduced by 25% in
subsequent cycles if there was persistent paresthesia between cycles or
paresthesia with functional impairment lasting more than 7 days. Treat-
ment was continued until there were signs of disease progression, devel-
opment of unacceptable toxic effects, or the refusal by patient of further
treatment.
3. Pretreatment and follow-up evaluation
Before each treatment courses, a physical examination, routine hema-
tologic studies, blood chemistry, and chest X-ray were performed. The
serum carcinoembyromic antigen (CEA) levels were determined after
each cycle. CT scans to define the extent and the response of the disease
were performed after 4 cycles of chemotherapy, or sooner if there was
evidence of any clinical deterioration. Patients were assessed before start-
ing each 2-week cycle using the NCI-CTC, except in the case of neuro-
toxicity. For the neurotoxicity, an oxaliplatin-specific 3-grade scale was
used: grade 1, paresthesias or dysesthesias of short duration, but resolving
before the next dosing; grade 2, paresthesias persisting between doses (2
weeks); and grade 3, paresthesias interfering with function.
4. Assessment of response
Responses were evaluated using RECIST criteria [13]. Complete re-
sponse (CR) was defined as the disappearance of all evidence of disease
and the normalization of tumor markers for at least 2 weeks. Partial re-
sponse (PR) was defined as ≥30% reduction in uni-dimensional tumorDong Hyun Lee, FOLFOX 4 for Peritoneal Carcinomatosis in Colorectal Cancer
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measurements, without the appearance of any new lesions or the progres-
sion of any existing lesion. Progressive disease (PD) was defined as any
of the following: 20% increase in the sum of the products of all measurable
lesions, appearance of any new lesion, or reappearance of any lesion that
had previously disappeared. Stable disease (SD) was defined as a tumor
response not fulfilling the criteria for CR, PR, or PD.
The dose-intensity (mg/m2/wk) was calculated as the total cumulative
dose divided by the duration of dosing. The relative dose-intensity (RDI)
was calculated as the dose-intensity divided by the planned dose-intensity,
multiplied by 100. The planned dose-intensities, expressed as milligrams
per square meter per week, were 1,000 for 5-FU and 42.5 for oxaliplatin.
5. Statistical methods 
This trial was designed to detect a response rate of 30%, as compared
with the minimal, clinically meaningful response rate of 10%. A two-stage
optimal design, as previously proposed, was adopted [14], with a statistical
power of 80% for hypothesis acceptance and 5% significance for hypoth-
esis rejection. Allowing for a follow-up loss rate of up to 10%, the total
sample size required was 35 patients with measurable disease. Categorical
variables in the two groups were compared by the ˇ2test or Fisher’s exact
test. p-values＜0.05 were considered statistically significant and all p-val-
ues correspond to two-sided significance tests. The primary study endpoint
was from the time of diagnosis of PC to the time of death. TTP and overall
survival (OS) were calculated via the Kaplan-Meier method. TTP was
calculated from the date therapy was initiated to the date of disease pro-
gression, death, or final follow-up. OS was calculated from the date ther-
apy was initiated to the date of death or final follow-up. The log-rank test
was employed to compare distributions. Due to the small number of pa-
tients the performance of a multivariate analysis was not considered to be
useful. All data were analyzed with SPSS ver. 18.0 (SPSS Inc., Chicago,
IL).
R esults
1. Patient characteristics
Beginning in January 2002, 40 patients were assigned for treatment at
the Department of Internal Medicine at the Dong-A University Medical
Center in Busan, Korea. The male to female ratio in this study was 20 :
20, and the median patient age was 55 years (range, 28 to 75 years). PC
was present at time of resection of the primary tumors in 24 patients, and
it was diagnosed as recurrent disease in 16 patients with an average dis-
ease-free interval of 16.5 months (range, 0 to 33 months). Thirty-two pa-
tients (80.0%) received a previous operation, and ascites was present at
diagnosis of the primary tumor in 20.0% of patients. Thirty-two patients
(80.0%) were judged to have an ECOG performance status of 0-1. Thirty-
five patients (87.5%) initially presented with at least one measurable le-
Table 1. Univariate analysis of time to progression and overall survival according to the clinicopathologic findings
TTP, time to progression; OS, overall survival; ECOG, Eastern cooperative oncology group; PS, performance status; PC, peritoneal carcinomatosis;
CEA, carcinoembryonic antigen.
No. TTP (mo) p-value OS (mo) p-value
Gender Male 20 5.0 0.054 22.5 0.352
Female 20 3.8 15.5
Age (yr) ＜60 26 5.4 0.661 22.1 0.436
≥60 14 2.9 14.6
Site Colon 29 4.3 0.763 21.5 0.317
Rectum 11 7.1 25.9
ECOG PS 0-1 32 5.4 0.039 22.5 0.040
28 1.5 6.8
No. of metastasis 2 30 5.0 0.153 22.5 0.749
＞2 10 2.5 12.3
Liver metastasis - 27 6.2 0.022 22.5 0.994
+ 13 2.8 21.5
Lung metastasis - 34 4.4 0.570 22.5 0.120
+6 2.5 14.6
Time of PC Synchronous 24 4.3 0.349 22.1 0.919
Metachronous 16 5.0 19.1
Ascites - 32 4.4 0.696 19.2 0.952
+8 2.5 22.5
CEA (ng/mL) ＜58 7.1 0.016 37.2 0.001
≥5 32 3.0 15.6Cancer Res Treat. 2011;43(4):225-230
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sion. The most frequent site of involvement was abdominal lymph node
(50.0%), followed by the liver (32.5%), ovary (20.0%), and lung (15.0%).
2. Response and toxicities
Thirty-five patients were assessed for response with measurable lesions.
Two patients achieved CR (5.7%), 5 patients showed PR (14.3%), 17 pa-
tients (48.6%) had SD, and 11 patients (31.4%) manifested PD. Patients
who had liver metastasis displayed a better response rate (31.8% vs. 0%,
p=0.031). Patients with low serum CEA also showed better response
(57.1% vs. 10.7%, p=0.018). Forty patients received a total of 294 treat-
ment cycles. The median number of cycles administered was 6 cycles
(range, 2 to 12 cycles). Dose reductions were required on nine occasions.
The dose intensities of oxaliplatin and 5-FU were 40.6 mg/m2/wk and
976.5 mg/m2/wk, and the RDIs of oxaliplatin and 5-FU were 95.5 and
97.7%.
Toxicities observed during the treatment are as follows. Grade 1 or 2
anemia (50.0%) was the most frequently observed hematological toxicity,
and grade 3 or 4 neutropenia was detected in 15.5% of the cycles. Nine
cycles (3.1%) of febrile neutropenia were recorded, and grade 2 or 3 nau-
sea/vomiting were noted in 6 patients (15.0%). Grades 1 and 2 neuropathy
was observed in 6 patients (15.0%). However, no patients experienced
neuropathy of grade 3 or more. No treatment related deaths occurred in
this study.
3. Survival  
The median follow up duration was 22.9 months (range, 2.4 to 71.8
months). The median TTP was 4.4 months (95% confidence interval [CI],
2.5 to 6.3 months), and the median OS duration was 21.5 months (95%
CI, 17.2 to 25.7 months). TTP and OS were evaluated via Kaplan-Meier
analysis, as shown in Figs. 1 and 2. Several potential prognostic factors
were analyzed for survival differences: ECOG performance status, dis-
ease-free interval, presence of liver, lung metastases and ascites, and serum
CEA level (Table 1). Presence of liver metastasis (p=0.022), performance
status (p=0.039), and CEA level (p=0.016) were related to the TTP. Pa-
tients with low CEA level (37.2 months vs. 15.6 months, p=0.001), or
good performance status (22.5 months vs. 6.8 months, p=0.040) showed
better OS. No other intrinsic patient and tumor characteristics involved in
the univariate analysis seemed to have a clear influence on OS. Given
these results, performing a multivariate analysis would not have been use-
ful.
Discussion
A subgroup of patients presenting with isolated intraperitoneal metas-
tases without evidence of systemic disease contributed to the development
of new locoregional treatment strategies consisting of CRS and HIPEC.
In selected patients, this aggressive surgical approach results in a signifi-
cant survival benefit [9]. Unfortunately, only a small and highly selected
group of patients with limited disease confined to the peritoneal cavity is
eligible for this treatment, therefore most patients suffering from PC are
dependent on palliative systemic chemotherapy. 
Chu et al. [4] reported on a series of 100 patients with PC of nongyne-
cologic tumors, among whom 45 patients had CRC. In the patients with
Fig. 1. Time to progression curve. Median time to progression was
4.4 months (95% confidence interval, 2.5 to 6.3 mo). 
Fig. 2. Overall survival curve. Median overall survival was 21.5
months (95% confidence interval, 17.2 to 25.7 mo).Dong Hyun Lee, FOLFOX 4 for Peritoneal Carcinomatosis in Colorectal Cancer
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CRC, of whom the majority was treated with 5-FU and LV, median sur-
vival was 6 months. Shorter disease-free interval, presence of lung metas-
tases, and presence of ascites correlated significantly with decreased
survival [4]. A multi-centre prospective study (EVOCAPE1) reported on
118 patients with PC from CRC with a median survival of 5.2 months
[13]. Only the extent of PC was significantly correlated to survival. Syn-
chronous PC, T stage, lymph node involvement, tumor differentiation,
presence of ascites, and presence of liver metastases did not have a statis-
tically significant influence on prognosis. In a retrospective analysis of
3019 patients with CRC, 349 (13%) of the patients presented with PC,
214 patients (7%) had synchronous PC at the time of resection of the pri-
mary tumor, whereas another 135 patients (4.5%) developed metachro-
nous carcinomatosis [6]. The 349 patients who presented with PC had a
median survival of 7 months. In the PC group, a significantly higher pro-
portion of primary tumors had advanced disease stage at diagnosis. Fur-
thermore, extent of PC disease and T stage were identified as predictors
of survival for synchronous PC. In a phase III randomized controlled trial
of 50 patients who were treated with systemic chemotherapy and palliative
surgery obtained an overall median survival of 12.6 months with a 2-year
survival rate of 18% and a median time to disease progression of 7.6
months [12].
Although the favorable effect of modern chemotherapy treatment on
the survival of patients with metastatic disease in general has been well
described, it remains unclear whether these systemic therapies have the
same beneficial impact on the outcomes of the subset of patients diagnosed
with PC. Despite increasing usage of palliative chemotherapy and avail-
ability of new agents, population-based survival of patients with PC has
not improved until very recently. Response to palliative chemotherapy in
PC should be evaluated separately from hematogenous metastases. At the
present time, there is only one published study that outlines the impact of
the new systemic therapy regimens when given to CRC patients with PC
[15]. The study reported a median survival of 5 months (95% CI, 3 to 7
months) for patients who had no chemotherapy, 11 months (95% CI, 6 to
9 months) for patients treated with 5-FU/LV, and 12 months (95% CI, 4
to 20 months) for patients treated with oxaliplatin/irinotecan-based
chemotherapy. In our study, we observed that the median OS was 21.5
months, compatible with a previous study [10]. To our knowledge, such
high median OS has never been reported for patients with CRC with PC
in the literature, and may be due to the facts that most patients had good
performance status and the number of metastasis was less than three. This
is the highest median survival that can currently be obtained with systemic
treatment and without recent targeted therapies. We also showed that good
performance status and low level of CEA were related to better survival.
However, none of the above-mentioned adverse predictive factors in other
studies had a statistically significant influence on outcome. 
C onclusion
Our data demonstrates that m-FOLFOX4 is likely to be beneficial in
patients with PC of CRC, especially the patients with good performance
status and low CEA. The results of this study support the rationale for pal-
liative treatment with the best available systemic chemotherapy schedules
for patients with PC who do not meet the inclusion criteria for CRS and
HIPEC. Future research should focus on developing the optimal combi-
nation of palliative chemotherapy regimens for patients suffering from
PC of CRC. 
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